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Background: Urethral metastatic adenocarcinoma is extremely rare. Moreover, only 9 previous cases with metastases
from colorectal cancer have been reported to date, and not much information on urethral metastases from colorectum
is available so far.
Case presentation: We report our experience in the diagnosis and the management of the case with urethral
metastasis from a sigmoid colon cancer. A 68-year-old man, who underwent laparoscopic sigmoidectomy for sigmoid
colon carcinoma four years ago, presented gross hematuria with pain. Urethroscopy identified a papillo-nodular tumor
7 mm in diameter in the bulbar urethra. CT-scan imaging revealed the small mass of bulbous portion of urethra and
solitary lung metastasis. Histological examination of the tumor obtained by transurethral resection showed moderately
differentiated adenocarcinoma, which was diagnosed as a metastasis of a sigmoid colon carcinoma pathologically by
morphological examination. Immunohistochemical analysis of the urethral tumor revealed the positive for cytokertin 20
and CDX2, whereas negative for cytokertin 7. These features were consistent with metastatic adenocarcinoma of the
sigmoid colon cancer. As the management of this case with urethral and lung metastasis, 6-cycle of chemotherapy
with fluorouracil with leucovorin plus oxaliplatin was administered to the patient, and these metastases were
disappeared with no recurrence of disease for 34 months.
Conclusion: Urethral metastasis from colorectal cancer is a very rare occurrence. However, in the presence of urinary
symptoms, the possibility of the urethral metastasis should be considered.
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Urethral tumors are rare. Most of urethral tumors are
primary origins, and Surveillance, Epidemiology and End
Results (SEER) study reported that an annual age-
adjusted incidence rate of primary urethral tumors was
4.3 per million in males and 1.5 per million in females in
the United States [1]. Histologically, squamous cell
carcinoma or transitional cell carcinoma is the common
types, accounting for about 80% of all cases. Adenocarcin-
oma from paraurethral glands accounts for 10-20% of
urethral primaries [2]. In addition, melanomas and various
sarcomas have been reported. On the other hand, urethral
metastatic tumor, especially adenocarcinoma, is extremely* Correspondence: kaz-tky@umin.ac.jp
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reproduction in any medium, provided the orrare. In these cases, prostatic carcinoma, lung cancer, and
colorectum have been described to metastasize to the
urethra [3,4]. However, not much information on urethral
metastases from these primaries is available so far. To our
knowledge, only 9 previous cases with metastases from
colorectal cancer have been reported to date [2,5-10]. We
report a case of urethral metastasis from a sigmoid colon
carcinoma with remaining free of tumor for 34 months,
mainly from immunohistopathological point of view to
add to some knowledge about its management and mech-
anism for metastasis.
Case presentation
A 68-year-old man presented gross hematuria with pain
and was hospitalized in June 2011. Four years ago, he had
undergone laparoscopic sigmoidectomy for sigmoid colon
carcinoma (stage B of Dukes’ classification). Histologicall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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ately differentiated adenocarcinoma. Postoperative adju-
vant chemotherapy was not carried out and he went to
hospital regularly for postoperative observation.
At the time of hospitalization, nodular induration was
not noted. Tumor marker such as the carcinoembryonic
antigen was slightly elevated (5.1 ng/mL, normal range,
0–5.0). Urethroscopy identified a papillo-nodular tumor
7 mm in diameter in the bulbar urethra (Figure 1a). Biopsy
of the tumor revealed adenocarcinoma, which suggested
primary urethral tumor or metastasis of the sigmoid colon
cancer. Barium enema examination and colonofiberscopy
showed no reccurence of cancer. CT-scan imaging re-
vealed the small mass of bulbous portion of urethra
(Figure 1b) and solitary lung metastasis. A transurethral
resection of the tumor was performed under the spinal
anesthesia. Histological examination showed moderately
differentiated adenocarcinoma, which was diagnosed as a
metastasis of a sigmoid colon carcinoma pathologically by
morphological examination with hematoxylin and eosin
staining (Figure 2). Moreover, immunohistochemistry of
the urethral tumor showed the positive for cytokertin
(CK) 20 and CDX2, the intestinal epithelia-specific nuclear
transcription factor, whereas negative for CK7 (Figure 3).
These features were consistent with metastatic adenocar-
cinoma of the sigmoid colon cancer. Additional therapy
whether surgical resection (partial penectomy and partial
excision of the lung) or systemic chemotherapy was pro-
posed to the patient, and systemic chemotherapy wasFigure 1 Urethral tumor detected four years after sigmoidectomy. (a)
the urethral wall of the distal-potion from the urethral sphincter. (b) Cystos
recurrence of the tumor. (c) CT-scan imaging showed the small mass of bu
the total disappearance of urethral metastasis.selected. The patient received 6 cycle of chemotherapy with
fluorouracil with leucovorin plus oxaliplatin (FOLFOX4).
CT-scan and MRI imaging after 6-cycle FOLFOX4 revealed
the total disappearance of both urethral and lung metastasis
(Figure 1c). After the induction chemotherapy, the patient
received daily tegafur, gimeracil and oteracil (TS-1; 80 mg/
day) and was under careful surveillance with CT scan and
periodical measurement of serum carcinoembryonic anti-
gen level. Although he is a high-risk patient of recurrent,
he is healthy with no evidence of recurrence at about
34 months of follow-up to date.
Conclusions
We had an experience with the case of urethral metastasis
from a sigmoid colon cancer in male. In this case, urethral
tumor was considered to have metastasized from colon
cancer pathologically by both morphological examination
with hematoxylin and eosin staining and immunohisto-
chemical examination. As to the immunohistochemical
analysis, the expression of CK20, CK7, and CDX2 was
useful for identifying the primary site of metastatic adeno-
carcinoma. T. Tot summarized the results of 29 studies
about for CK20/CK7 phenotype, and stated that colorectal
carcinomas showed the CK20+/CK7- phenotype in 78% of
the cases and were concluded to be usually CK20+ and
CK7- [11]. Therefore, the CK20+/CK7- phenotype indi-
cates metastatic adenocarcinoma, most often from the
colorectum. In regard to CDX2, Barbareschi et al. showed
that CDX2 immunostained all colorectal adenocarcinomasCystoscopy demonstrated papillary tumor of approximate 7 mm in
copy demonstrated scar of the transurethral resection without
lbous portion of urethra (white arrow). (d) CT-scan imaging showed
Figure 3 Immunohistochemical staining of urethral tumor
using an anticytokeratin antibody, (a) CK20 and (b) CK7
(original magnification, ×20), and using an antibody against
the intestinal epithelia-specific nuclear transcription factor,
(c) CDX2 (original magnification, ×20). The immunohistochemical
phenotype showed CK20+/CK7-/CDX2 +.
Figure 2 Urethral tumor showed moderately differentiated
adenocarcinoma consistent with sigmoid colon cancer (original
magnification, ×20).
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all primary lung neoplasm and in all other adenocarcinoma
metastatic to the lung [12]. However, CDX2 is not entirely
specific for colorectal cancer, because Weling RW et al.
reported that the expression of CDX2 was found ovarian
mucinous carcinoma, adenocarcinoma of the urinary blad-
der, and prostatic adenocarcinoma [13]. The present case
exactly showed the phenotype of CK20+/CK7-/CDX2+,
suggesting that the urethral tumor was derived from
primary tumor of sigmoid colon.
Colorectal cancer with urethral metastasis is generally
considered a systemic disease, and the prognosis is gen-
erally poor according to the previous case report [8].
Moreover, patients with metachronous metastases were
considered to have a worse prognosis than those with
synchronous metastases [8]. The clinicopathological fea-
tures of these 9 patients with urethral metastasis from
colorectal cancer are shown in Table 1. The average size
of urethral tumor was 2.3 cm. Moreover, the average
duration of the detection of metachronous urethral
metastasis postoperatively was 2.7 years. In comparison,
the urethral metastasis in the present case was detected
as a mass with relatively small size and at a long postop-
erative interval, which might be the reason of the better
outcome in current cases. The cases with synchronous
reccurence were three, and all cases were female. Among
them, two cases (67%) were alive without symptoms of re-
currence for 6 and 30 months, respectively. In contrast,
the patients with metachronous were 6, and all cases were
male including our case. Only two cases (33%) were alive
without symptoms of recurrence for 20 and 84 months,
respectively. In the present case, both urethral and solitary
lung metastasis were detected after curative surgery for
sigmoid colon cancer. Additional therapy whether surgical
resection or systemic chemotherapy was considered.
Recently, neoadjuvant therapy using FOLFOX (withapproved biological agent) chemotherapy was recom-
mended as a nonsurgical management of patients with no
obstructing metastatic (stage IV) colorectal cancer, and
demonstrated excellent result with few complications [14].
This suggests nonsurgical chemotherapy using FOLFOX
plus biological antibodies might have beneficial effect on
patients with urethral metastasis from colorectal cancer.
Therefore, 6-cycle FOLFOX4 was administered to the
patient after informed consent about additional therapy,
Table 1 Characteristics of the patients with urethral metastasis from colorectal cancer
Author Age Gender Primary site Stage Recc Interval Size Symptom Operation Aduvant therapy Outcome
1 Selikowitz SM et al [5]. 48 M Rectum NS M 5Y NS Urinary obstruction None None 6 M Dead
2 75 M Sigmoid Dukes’ D M 6 M NS Slowig of the urinary stream None Chemo + iridium 2 M Dead
3 Okaneya T et al [6]. 47 M Sigmoid Dukes’ C M 2Y NS Gross hematuria Resection None 84 M Alive
4 Stragier J et al [7]. 68 F Rectosigmoid Dukes’ D S NS 1 cm Obstructive micturition Anterior resection + wedge
resection
Rad + Chemo 6 M Alive
5 Kupfer HW et al [8]. 67 M Rectum Dukes’ B M 3Y NS Voiding difficulties apalpable
painless tumor
Partial resection Rad 10 M Dead
6 Chitale Sv et al [2]. 60 F Sigmoid Dukes’ B S NS 2.5 cm None Cystourethrectomy + bil.
salphingo oopharectomy
None 30 M Alive
7 72 M Rectum Dukes’ B M 2Y 2 cm Strangury mild irritative lower
urinary tract symptoms
None None 6 M Dead
8 Chang YH et al [9]. 62 M Ascending Dukes’ B M 2Y7M 3.5 cm Intermittent gross hamaturia Partial penectomy Rad + Chemo 20 M Alive
9 Noorani S et al [10]. 69 F Sigmoid NS S NS NS Swelling at the urethral
opening
Anterior resection + pelvic
exentration
None NS
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of disease. This aggressive chemotherapy might help to
improve the disease free survival and patient’s overall
quality of life.
Possible mechanisms for metastatic spread to the penis
have been described as direct arterial extension, secondary
and tertiary embolism, instrumental spread, paradoxical
embolism, retrograde lymphatic spread and direct exten-
sion [15]. Of these, the latter three mechanisms are
considered to be most likely, when the primary tumor
arises from the rectosigmoid colon. Batson OV described
that the communication between pelvic and vertebral
veins would easily account for retrograde venous spread
during Valsalva maneuvers when proximal venous chan-
nels are blocked with tumor [16]. Selikowitz SM et al. also
described that blockage of proximal lymphatics might
allow retrograde lymphatic spread to occur via connections
between inferior hemorrhoidal and pudendal lymphatics,
and direct extension was possible from the ischiorectal
fossa, through the junction of Collees fascia with the
triangular ligament, to the superficial perineal pouch.
Nevertheless, the number of the cases with urethral metas-
tasis was few. Moreover, only 3 cases (33%) out of nine
cases that were reported previously had lymph node
metastasis (stage C of Dukes’ classification) or distant me-
tastasis (stage D of Dukes’ classification). The accumulation
of these cases is necessary for exact clarification of the
mechanism for metastasis to the urethra.
In patients with colorectal cancer, postoperative follow-
up, including tumor markers (carcinoembryonic antigen,
carbohydrate antigen 19–9, and serum p53 antibody),
chest X-ray, liver ultrasound, computed tomography, and
colonofiberscopy is routinely performed. Urethral metas-
tasis from colorectal cancer is a very rare occurrence.
Therefore, the examination of the urinary system as a part
of the routine postoperative follow-up protocol would not
be justified. However, in the presence of urinary symp-
toms, the possibility of the urethral metastasis should be
considered.Consent
Written informed consent was obtained from the patient
for publicatin of this Case report and any accompanying
images. A copy of the written consent is available for
review by the Editor of this journal.Abbreviations
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